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Abstract
Background: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT) is a randomized, double-blind, active-controlled trial designed to compare the rate of
coronary heart disease events in high-risk hypertensive participants initially randomized to a
diuretic (chlorthalidone) versus each of three alternative antihypertensive drugs: alpha-adrenergic
blocker (doxazosin), ACE-inhibitor (lisinopril), and calcium-channel blocker (amlodipine).
Combined cardiovascular disease risk was significantly increased in the doxazosin arm compared
to the chlorthalidone arm (RR 1.25; 95% CI, 1.17–1.33; P < .001), with a doubling of heart failure
(fatal, hospitalized, or non-hospitalized but treated) (RR 2.04; 95% CI, 1.79–2.32; P  < .001).
Questions about heart failure diagnostic criteria led to steps to validate these events further.
Methods and Results: Baseline characteristics (age, race, sex, blood pressure) did not differ
significantly between treatment groups (P < .05) for participants with heart failure events. Post-
event pharmacologic management was similar in both groups and generally conformed to accepted
heart failure therapy. Central review of a small sample of cases showed high adherence to ALLHAT
heart failure criteria. Of 105 participants with quantitative ejection fraction measurements
provided, (67% by echocardiogram, 31% by catheterization), 29/46 (63%) from the chlorthalidone
group and 41/59 (70%) from the doxazosin group were at or below 40%. Two-year heart failure
case-fatalities (22% and 19% in the doxazosin and chlorthalidone groups, respectively) were as
expected and did not differ significantly (RR 0.96; 95% CI, 0.67–1.38; P = 0.83).
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Conclusion: Results of the validation process supported findings of increased heart failure in the
ALLHAT doxazosin treatment arm compared to the chlorthalidone treatment arm.
The Antihypertensive and Lipid Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT) is a randomized,
two-component clinical trial sponsored by the National
Heart, Lung, and Blood Institute (NHLBI). A double-
blind, active-controlled hypertension component is de-
signed to compare the rate of fatal coronary heart disease
(CHD) or nonfatal myocardial infarction (MI) (the pri-
mary endpoint) in high-risk hypertensive participants,
aged 55 years or older, between those randomized to
treatment initiated with a diuretic (chlorthalidone) and
treatment initiated with each of three alternative antihy-
pertensive drugs: a calcium-channel blocker (am-
lodipine), an angiotensin-converting enzyme (ACE)-
inhibitor (lisinopril), or an alpha-adrenergic blocker
(doxazosin). An open-label lipid-lowering component is
designed to determine if lowering LDL cholesterol with
pravastatin compared to "usual care" reduces all-cause
mortality in a subset of moderately hypercholesterolemic
patients. Randomization to the hypertension component
began in February, 1994, and continued through January,
1998, with 42,418 participants recruited at 623 clinical
centers in the United States, Canada, Puerto Rico and the
US Virgin Islands. Randomization of 10,355 participants
into the lipid trial ended May 31, 1998. Follow-up on all
participants continued through March, 2002 [1].
Following independent reviews by the Data and Safety
Monitoring Board (DSMB) on January 6, 2000, and by an
Ad Hoc Committee on January 21, 2000, the Director of
the National Heart, Lung, and Blood Institute accepted a
recommendation to discontinue the doxazosin treatment
arm of the antihypertensive trial. This recommendation
was based on the low probability of doxazosin showing
benefit over chlorthalidone for the primary endpoint, as
well as the significantly increased occurrence of the sec-
ondary endpoint, combined cardiovascular disease
(CVD) (encompassing CHD deaths, nonfatal MI, stroke,
coronary revascularization procedures [coronary artery
bypass graft or CABG, percutaneous transluminal coro-
nary angioplasty or PTCA/stent], angina [hospitalized or
treated as an outpatient], heart failure [HF/treated in the
hospital or as an outpatient], and peripheral arterial dis-
ease [in-hospital or outpatient revascularization]) in the
doxazosin arm (RR 1.25; 95% CI, 1.17–1.33; P < .001),
with a doubling of risk of HF (fatal, hospitalized and treat-
ed but nonhospitalized) (RR 2.04; 95% CI, 1.79–2.32; P
< .001). When only fatal and hospitalized HF were ana-
lyzed, the large difference remained (RR 1.83; 95% CI,
1.58–2.13;P < .001). The findings and operational aspects
of stopping the doxazosin arm of the study have been pre-
viously described [2–4].
The observed increase in HF in the doxazosin group as
compared to the chlorthalidone group led to several addi-
tional analyses aimed toward validation of the diagnoses,
with a focus on hospitalized and fatal HF. The purposes of
these analyses were: 1) to evaluate the reality of HF cases,
i.e. whether diagnosis, management, and clinical course
were what might be expected, and 2) to compare these
features between the two treatment groups.
Methods
Study Design
The rationale and design of ALLHAT are described in de-
tail elsewhere [1]. Briefly, those eligible for randomiza-
tion had systolic blood pressure (SBP) of at least 140 mm
Hg and/or diastolic blood pressure of at least 90 mm Hg,
or took medication for hypertension, and had at least one
other risk factor for CHD events. Risk factors included pre-
vious MI or stroke, left ventricular hypertrophy by electro-
cardiogram or echocardiogram, history of type 2 diabetes,
current cigarette smoking, and low high-density lipopro-
tein (HDL) level.
The primary endpoint of the blood pressure (BP) trial is
the composite of nonfatal MI and fatal CHD. The four
protocol-defined secondary clinical outcomes are all-
cause mortality, combined CHD (including CHD death,
nonfatal MI, coronary revascularization procedures and
hospitalized angina), stroke, and combined CVD (includ-
ing CHD death, nonfatal MI, stroke, coronary revasculari-
zation procedures, angina treated in the hospital or as an
outpatient, lower extremity peripheral arterial disease
treated in the hospital or with outpatient revasculariza-
tion, and HF, fatal or treated in the hospital or as an out-
patient).
The validation of HF diagnosis entailed answering several
questions:
1. Did HF cases meet ALLHAT diagnostic criteria?
2. Were baseline characteristics and medical management
for HF cases as expected and similar across the drug
groups?
3. Were prevalence and severity of systolic dysfunction as
expected and similar across drug groups?Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/10
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4. Were case-fatality rates as expected and similar across
drug groups?
Unless otherwise specified, all data for these analyses were
collected as of December, 1999.
Heart Failure Diagnosis
At each follow-up clinic visit the occurrence of study clin-
ical events was assessed, and, if identified by the clinical
investigator, reported on an endpoint form. For each
event involving hospitalization, a hospital discharge sum-
mary or expiration summary was to be submitted, and for
each death a death certificate was required. Endpoint
forms and supporting documentation were reviewed at
the ALLHAT Clinical Trials Center (CTC) for accuracy and
appropriateness. When a discrepancy or ambiguity was
found, the CTC sent a written query to the Principal Inves-
tigator, who retained the final word concerning the diag-
nosis or cause of death. A random 10% sample of strokes,
nonfatal MIs and CHD deaths was selected for blinded
quality control evaluation by the ALLHAT Endpoints Sub-
committee; for these cases additional documentation was
requested.
No such routine Endpoints Subcommittee quality control
was initially planned for reported HF. However, the Sub-
committee was subsequently called upon to evaluate a
random sample of reported fatal and hospitalized nonfa-
tal HF events. As this occurred prior to the termination of
the doxazosin arm, neither the chair nor the members of
the Subcommittee was informed of the major reason for
this review, namely, the trend toward a higher HF event
rate in the doxazosin group compared to the chlortha-
lidone group. The Subcommittee was told that the review
was undertaken at the request of the DSMB to address the
reliability and validity of reported HF events. This evalua-
tion consisted of fifty events, evenly distributed across the
four treatment groups, reported as fatal or hospitalized
nonfatal HF and with protocol-required documentation
(discharge summary for hospitalized events, death certifi-
cates for deaths). Additional material was not requested,
since this would have posed an undue burden on the clin-
ical site staff and would have risked raising questions
about emerging differences among treatment groups.
The ALLHAT definition of HF, used previously in the
Systolic Hypertension in the Elderly Program (SHEP) [5],
includes "patients with clear-cut signs or symptoms of left
or right ventricular dysfunction that cannot be attributed
to other causes..." The diagnosis of HF must include at
least one of four stated symptoms [paroxysmal nocturnal
dyspnea, dyspnea at rest, New York Heart Classification
functional class III (for definition see Additional Informa-
tion, Item 1), or orthopnea], and one of seven stated signs
(rales, 2+ or greater ankle edema, tachycardia of 120
beats/minute or more after five minutes at rest, cardiome-
galy by chest x-ray, chest x-ray characteristic of HF, S3 gal-
lop, or jugular venous distention). Since lower extremity
edema or exertional dyspnea may be due to non-cardiac
causes, the presence of either of these alone, without other
indications of heart failure, is not sufficient for a diagnosis
of HF. Study guidelines caution against a hasty HF diagno-
sis in patients with severe pulmonary disease, including
chronic obstructive pulmonary disease (COPD), pneu-
monia, or other severe, documented lung disease.
Baseline Characteristics and Medical Management
Baseline characteristics of chlorthalidone and doxazosin
participants were compared. These analyses were stratified
by HF outcome: 1) fatal and hospitalized HF; 2) treated,
non-hospitalized HF; and, 3) no HF.
Post-HF event medical management may provide addi-
tional evidence of the physicians' confidence in the HF di-
agnosis. The post-event use of open-label diuretics, ACE-
inhibitors, and beta-blockers, i.e., accepted treatments for
HF [6–9], was compared between doxazosin and chlo-
rthalidone groups, as was the proportion in each group of
those who remained on assigned blinded medication after
the event. (For study guidelines regarding the use and re-
porting of open-label medicines of the same class as the
blinded drugs, see Additional Information, Items 2 and
3.)
Ejection Fraction Review
A CTC physician plus non-medical staff reviewed in a
blinded fashion 361 hospitalized HF events (representing
278 participants) for ejection fraction data: looking for
whether an ejection fraction was measured, the method
utilized, and the measurement. Results, tabulated by ran-
domization groups, reflected data that had been collected
up to July, 1999, the time of the review.
Case-Fatality Rates and Causes of Death
As a measure of the diagnostic validity and severity of HF
and comparability between drug groups, time-from-
event-to-death analyses of participants with hospitalized
or treated HF were compared between the two groups.
Causes of death of such participants were also compared
in the doxazosin and chlorthalidone groups.
Statistical Analyses
Data were analyzed according to participants' randomiza-
tion assignments and HF outcome status, regardless of
subsequent medication adherence. The Kaplan-Meier
method was utilized in calculating cumulative event rates.
Descriptive statistics by treatment groups were presented
for baseline characteristics, HF ascertainment, ejection
fractions and use of HF medications. Comparability ofCurrent Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/10
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baseline characteristics of the treatment and HF outcome
groups was ascertained by the χ2 test for categorical varia-
bles and standard normal (z) test for continuous varia-
bles.
Results
Heart Failure Diagnostic Criteria
The blinded review by the Endpoints Subcommittee of 50
fatal or hospitalized HF events from the 4 drug groups de-
termined 11 (22%) to have incomplete data for a defini-
tive review. Of the remaining 39, 33 (85%) were
confirmed to have HF by one or both reviewers. For both
the chlorthalidone and doxazosin groups, the diagnosis of
HF was confirmed in 90% (18/20).
Baseline Characteristics
Baseline characteristics for the doxazosin and chlortha-
lidone treatment groups, stratified for HF status, are de-
scribed in Table 1.
Baseline characteristics of doxazosin and chlorthalidone
participants with subsequent hospitalized or fatal HF were
compared. Doxazosin participants with hospitalized or
fatal HF had a higher baseline SBP than the chlortha-
lidone participants (150.1 vs. 147.8 mm Hg at the rand-
omization visit). More doxazosin participants had LVH by
ECG (22.3% vs. 20.5% of chlorthalidone participants);
slightly more chlorthalidone than doxazosin participants
had LVH by echocardiogram. Several eligibility risk fac-
tors, including previous MIs or strokes, coronary revascu-
larization procedures, other atherosclerotic cardiovascular
Table 1: Baseline Characteristics of Participants With and Without Heart Failure
Hospitalized and Fatal HF Treated, Nonhospitalized HF Without HF*
CDCDCD
No. of subjects 327 346 93 145 14493 8347
Age, years, mean (SD) 70.7 (8.3) 71.0 (8.6) 70.3 (8.2) 69.9 (7.2) 66.8 (7.6) 66.6 (7.6)
Race
White, non-Hispanic, % 61.2 55.8 63.4 64.8 47.3 46.3
Black, non-Hispanic, % 30.6 35.3 32.3 30.3 32.0 32.9
Hispanic, % 4.6 5.5 2.2 2.8 15.6 16.1
Other, % 3.7 3.1 2.2 2.1 5.1 4.8
W o m e n ,  % 4 2 . 83 9 . 63 3 . 34 4 . 14 7 . 04 6 . 5
Education, years, mean (SD) 10.5 (3.9) 10.7 (3.4) 11.3 (3.6) 12.1 (3.2) 11.0 (4.0) 11.0 (4.0)
Cigarette smoking, current, % 19.0 19.4 11.8 17.9 22.1 21.9
Antihypertensive treatment
T r e a t e d  >  2  m o n t h s ,  % 8 6 . 98 6 . 89 5 . 79 5 . 28 6 . 98 6 . 7
Treated < 2 months, % 3.3 3.3 1.1 0.0 3.3 3.3
Untreated, % 9.8 10.0 3.2 4.8 9.9 10.0
Blood pressure, mm Hg, mean (SD) 147.8/81.1 
(17.6/10.9)
150.1/81.8 
(16.5/11.0)
147.1/82.2 
(16.0/10.5)
145.9/82.0 
(15.8/10.6)
146.2/84.1 
(15.6/10.0)
146.1/84.1 
(15.7/10)
Pulse pressure, mm Hg, mean (SD) 66.7 (16.5) 68.3 (15.3) 64.9 (13.0) 63.9 (15.3) 62.1 (14.1) 62.1 (14.2)
Eligibility risk factors†
LVH
B y  e l e c t r o c a r d i o g r a m ,  % 2 0 . 52 2 . 31 8 . 32 1 . 41 6 . 11 6 . 1
By echocardiogram, % 6.3 4.7 4.4 1.4 4.6 4.6
O l d  M I  o r  s t r o k e ,  % 3 6 . 13 4 . 74 1 . 93 3 . 12 3 . 12 2 . 3
C A B G / A n g i o p l a s t y ,  % 2 2 . 61 8 . 52 5 . 82 6 . 21 2 . 91 2 . 6
A S C V D ,  % 3 3 . 32 9 . 23 1 . 23 1 . 02 3 . 42 4 . 6 ‡
T y p e  2  d i a b e t e s ,  % 4 6 . 84 8 . 34 3 . 04 0 . 73 5 . 93 4 . 7
H D L < 3 5  m g / d l ,  % 1 2 . 81 3 . 61 4 . 01 3 . 81 1 . 91 1 . 7
S T - T  w a v e  c h a n g e s ,  % 1 2 . 81 0 . 61 0 . 91 2 . 91 0 . 41 0 . 2
HF= Heart Failure C = Chlorthalidone treatment group D = Doxazosin treatment group mm Hg = millimeters mercury LVH = Left ventricular 
hypertrophy MI = Myocardial infarction CABG = Coronary artery bypass graft ASCVD = Atherosclerotic cardiovascular disease HDL = High-den-
sity lipoprotein *Only participants with at least one follow-up visit are included. 355 chlorthalidone and 229 doxazosin participants are excluded 
due to lack of at least one follow-up visit. †For trial eligibility, participants had to have at least 1 other risk factor in addition to hypertension. The 
indicated risk factors are not mutually exclusive or exhaustive and do not represent prevalence. ‡P = .0484Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/10
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disease (ASCVD), and ST-T wave changes, were reported
more often in chlorthalidone than in doxazosin partici-
pants, though the differences were not significant. Chlo-
rthalidone and doxazosin participants with hospitalized
or fatal HF had similar pre-trial antihypertensive treat-
ment durations. None of these differences was significant
at P < .05.
Participants with HF events displayed higher rates of most
cardiovascular risk factors compared to those without HF
events. Approximately 35–36% of chlorthalidone and
doxazosin participants with fatal or hospitalized HF had
reported prior MI or stroke as baseline eligibility risk fac-
tors, compared to 22–23% of those without HF (P  <
.001). Participants with hospitalized/fatal HF had signifi-
cantly higher rates of pre-randomization coronary artery
bypass grafts (CABGs) and coronary angioplasties (19–
23% of those with HF vs. 13% of those without; P < .001)
and other atherosclerotic cardiovascular disease (ASCVD)
(29–33% of those with HF vs. 23–25% of those without;
P < .001). Diabetes as a baseline risk factor occurred more
frequently in those with HF: 47–48% in those with HF,
35–36% in those without (P  < .001). Left ventricular
hypertrophy (LVH) by ECG was a risk factor in 21–22% of
those who later developed HF, compared with 16% of
those in each group who did not develop HF (P < .001).
Baseline pulse pressure (PP) showed some variation be-
tween participants who did and did not develop HF. For
participants with subsequent hospitalization or death
from HF, PP was 67 and 68 mm Hg for the chlorthalidone
and doxazosin groups, respectively. Treated, non-hospi-
talized participants showed a lower mean baseline PP of
65 (chlorthalidone group) and 64 mm Hg (doxazosin
group), and an even lower mean PP in those without HF
(62 mm Hg in each group).
Medical Management
Table 2 presents post-event pharmacologic treatment of
participants with HF and antihypertensive treatment of
participants without HF. Following hospitalization for
HF, 36% (83/232) of chlorthalidone participants and
45% (126/281) of doxazosin participants remained on
their blinded medications. Percentages of participants on
open-label diuretics and ACE-inhibitors were similar fol-
lowing the event: 58% (135/232) of chlorthalidone par-
ticipants and 64% (180/281) of doxazosin participants
were prescribed open-label diuretics; 39% (90/232) of
chlorthalidone participants and 41% (114/281) of doxa-
zosin participants were prescribed open-label ACE-inhib-
itors. Beta-blockers were prescribed for 14% of each group
following the event, which was actually somewhat less
than for participants who did not develop HF. Three-quar-
ters of hospitalized HF participants in each group (169/
232 in chlorthalidone group, 210/281 in doxazosin
group) received at least one of the three medications (di-
uretic, ACE-inhibitor, or beta-blocker) post-hospitaliza-
tion.
Among participants treated but not hospitalized for HF,
58% (54/93) of the chlorthalidone group and 64% (93/
145) of the doxazosin group remained on their blinded
medication. Over 60% of participants in each group were
prescribed open-label diuretics and over 30% received
ACE-inhibitors. Open-label beta-blocker use post-event
occurred in 19% (18/93) of the chlorthalidone group and
Table 2: Post-Event Pharmacologic Treatment of Participants With and Without Heart Failure
Hospitalized Heart Failure* Treated, Nonhospitalized 
Heart Failure*
Without Heart Failure†
CDCDCD
No. of participants 232 281 93 145 14493 8347
Post-event medication
Blinded medication, (%) 83 (35.8) 126 (44.8) 54 (58.1) 93 (64.1) 11247 (77.6) 6096 (73.0)
Open-label diuretic (%) 135 (58.2) 180 (64.0) 57 (61.3) 98 (67.6) 1279 (8.8) 1153 (13.8)
Open-label ACE-inhibitor (%) 90 (38.8) 114 (40.5) 31 (33.3) 44 (30.3) 1154 (8.0) 826 (9.9)
Open-label beta-blocker (%) 33 (14.2) 38 (13.5) 18 (19.4) 32 (22.1) 3149 (21.7) 2016 (24.0)
Open-label diuretic, ACE-inhibitor 
or beta-blocker (%)
169 (72.8) 210 (74.8) 72 (77.4) 119 (82.1) 4829 (33.3) 3347 (40.1)
C = Chlorthalidone treatment group D = Doxazosin treatment group ACE = Angiotensin converting enzyme *Represents data as of first clinic visit 
after event. † Represents data as of most recent clinic visit. All participants represented have at least one follow-up visit. 355 chlorthalidone and 229 
doxazosin participants are excluded due to lack of at least one follow-up visit.Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/10
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22% (32/145) of the doxazosin group, approximately the
same frequency as in participants without HF. In both
treatment groups, a diuretic, ACE-inhibitor or beta-block-
er was prescribed for over 75% of these participants (72/
93 in chlorthalidone group, 119/145 in doxazosin
group).
Ejection Fraction Review
Table 3 displays the ejection fraction data. About half
(178/361) of reviewed discharge summaries mentioned
ejection fractions measured during hospitalization, two-
thirds (116/169) of which had quantitative measure-
ments reported in the discharge summaries (data not giv-
en). Considering only the earliest ejection fraction
information ascertained for each HF participant, 63%
(29/46) of the chlorthalidone and 70% (41/59) of the
doxazosin participants had ejection fractions at or below
40%. Just under half (27/59) of the ejection fractions re-
ported in the doxazosin group were at or below 30%,
compared with one third (15/46) in the chlorthalidone
group. Two-thirds of ejection fractions were obtained by
echocardiograms, though catheterizations accounted for a
larger percentage of results in the doxazosin group than in
the chlorthalidone group (36% vs. 24%).
Causes of Death and 2-Year Case-Fatality
Causes of death of participants with previous HF hospital-
ization were distributed similarly in the two groups, with
slight variations. HF accounted for 21.2% (11/52) of the
deaths among chlorthalidone participants and 17.1%
(12/70) of the deaths among doxazosin participants. Over
half of the deaths in each group (29/52 in the chlortha-
lidone group; 43/70 in the doxazosin group) were due to
cardiovascular events. Fifteen percent (8/52) of deaths in
the chlorthalidone group were attributed to cancer, com-
pared to 9% (6/70) in the doxazosin group (Table 4).
Case-fatality for participants with hospitalized HF events
showed no significant differences (RR 0.96, 95% CI,
0.67–1.38, P = 0.83) between the two treatment groups
(Figure 1). Among participants in the doxazosin treat-
ment group who had been previously hospitalized for HF,
22.1% (70/317) subsequently died, compared to 18.6%
(52/280) of those in the chlorthalidone group (Table 4).
As previously reported, all-cause mortality did not signifi-
cantly differ in the two treatment groups (RR 1.03, 95% CI
0.90–1.15, P = 0.56) [2].
Discussion
The finding of significantly increased HF events in the
doxazosin group compared with the chlorthalidone
group created a dilemma for ALLHAT. Since the trial was
not designed to focus on HF, a component of a secondary
endpoint, the validity of reported HF events became an is-
sue. In this paper, we have described several analyses to
address this concern.
As previously reported, lost-to-follow-up and event docu-
mentation were similar in the two treatment groups [2].
Steps employed to validate the HF outcome in these treat-
ment groups confirmed the consistency of HF event re-
porting. Participants in the two drug groups had similar
Table 3: Ejection Fraction Data for Participants Hospitalized with Heart Failure*
Chlorthalidone Treatment 
Group
Doxazosin Treatment 
Group
Total
Participants with hospitalized heart failure 245 296 541
Hospitalized heart failure participants reviewed 134 144 278
Total reviewed heart failure participants with quantitative 
ejection fractions†
46 59 105
By cardiac catheterization (%) 11 (23.9) 21 (35.6) 32 (30.5)
By echocardiogram (%) 33 (71.7) 37 (62.7) 70 (66.7)
Method not given (%) 2 (4.3) 1 (1.7) 3 (2.9)
Ejection fraction (%)‡
1–30% 15 (32.6) 27 (45.8) 42 (40.0)
31–40% 14 (30.4) 14 (23.7) 28 (26.7)
41–50% 9 (19.6) 7 (11.9) 16 (15.2)
51–60% 3 (6.5) 10 (16.9) 13 (12.4)
>60% 5 (10.9) 1 (1.7) 6 (5.7)
*Evaluation of documentation for ejection fractions was completed in July, 1999, 6 months prior to the decision to discontinue the doxazosin arm 
of ALLHAT. Total numbers of events and participants with heart failure in Table 3 are based on data at the time of review. †Event documentation 
which referred to ejection fraction measurements but which did not provide numeric values was excluded from this tally. ‡Ejection fraction for a 
participant is based upon the earliest post-randomization heart failure hospitalization with quantitative ejection fraction information provided.Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/10
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baseline characteristics when stratified by HF status. The
differences in eligibility risk factors between those partici-
pants with HF and those without is not surprising: larger
percentages of those with HF had a history of MI, stroke,
CABG, angioplasty, other atherosclerotic cardiovascular
disease (ASCVD), diabetes, low HDL levels and ECG ab-
normalities. Nonetheless, these eligibility factors were not
substantially different between chlorthalidone and doxa-
zosin participants with HF.
Post-diagnosis pharmacologic management of patients is
one measure of the strength of physicians' confidence in
the HF diagnoses. Open-label diuretics, ACE-inhibitors
and beta-blockers, all recognized treatments for HF, were
prescribed similarly for the chlorthalidone and doxazosin
groups, suggesting similar assessment of these events in
the two treatment groups.
ALLHAT criteria for HF were equivalently met in the two
groups. While the sample (n = 50) of hospitalized or fatal
HF reports reviewed by the ALLHAT Endpoints Subcom-
mittee was limited in number and in adequacy of corrob-
orating documentation, the review nonetheless showed
adherence to study criteria for the majority (85%) of the
event reports. The sometimes-discrepant results between
reviewers pertained more often to incomplete data than to
rejection of a HF diagnosis.
Clinical use of more objective measures, including nonin-
vasive and/or invasive tools for the measurement of left
ventricular function, offers a means of establishing and
quantifying systolic failure in cases clinically suggestive of
HF [7,10]. Among the ejection fractions reported in the
ALLHAT events that were reviewed, the majority fell at or
below 40%, indicating some degree of systolic dysfunc-
tion. However, HF is a clinical diagnosis that does not nec-
essarily exclude those with intact left ventricular systolic
function [11]. Hypertension is a major risk factor for di-
astolic HF; as many as 25% of asymptomatic hyperten-
sives with left ventricular hypertrophy have diastolic
dysfunction. Additionally, 90% of patients with coronary
artery disease may have some degree of diastolic dysfunc-
tion [12].
The two-fold increased relative risk of HF in the doxazosin
group compared to the chlorthalidone group changed lit-
tle when confined to hospitalized and fatal events. Fur-
ther, HF patients in both the doxazosin and
chlorthalidone treatment groups showed a rather high
20% case-fatality rate over two years, as expected in HF pa-
tients [11,13,14], further supporting the validity of the di-
agnoses in the two groups. Among participants
hospitalized for HF who subsequently died, over half of
the deaths in each drug group were attributed to cardio-
vascular causes.
Treatment group differences in mortality attributed to HF
may take time to be recognized. Patients with HF are at
risk for other competing causes of death. Accordingly, it
may be too early to determine if a higher rate of HF in the
doxazosin group translates into a higher overall mortality
rate. A 20% 2-year case-fatality rate with a 4% difference
in HF incidence rate translates into a 0.8% potential dif-
ference in total mortality without any competing causes of
Table 4: Causes of Death of Participants with Prior Heart Failure Hospitalization
Chlorthalidone Treatment Group Doxazosin Treatment Group
No. of participants with hospitalization for heart 
failure prior to death*
280 317
No. of deaths (%) 52 (18.6) 70 (22.1)
Cause of death (%)
Myocardial infarction 7 (13.5) 5 (7.1)
Definite CHD 5 (9.6) 9 (12.9)
Possible CHD 1 (1.9) 7 (10.0)
Stroke 1 (1.9) 3 (4.3)
Heart failure 11 (21.2) 12 (17.1)
Other CVD 4 (7.7) 7 (10.0)
Total cardiovascular deaths (%) 29 (55.8) 43 (61.4)
Cancer 8 (15.4) 6 (8.6)
Kidney disease 1 (1.9) 1 (1.4)
Accident/suicide/homicide 0 (0) 1 (1.4)
Other non-CVD 8 (15.4) 11 (15.7)
Unknown 6 (11.5) 8 (11.4)
CHD = Coronary heart disease CVD = Cardiovascular disease *Excludes participants for whom death is the first reported heart failure eventCurrent Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/10
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death. With competing causes, the difference would be
smaller and difficult to detect even in a trial of ALLHAT's
size.
The diagnosis of HF is generally made on the basis of signs
and symptoms that may overlap with those of other cardi-
ovascular and pulmonary pathologies. Moreover, the clin-
ical picture may be further complicated for patients taking
doxazosin, side effects of which (edema, dyspnea, and
tachycardia) [15] may be misinterpreted as manifesta-
tions of HF.
The capture of events in a "large and simple trial" such as
ALLHAT has potential limitations. Built into a structure
composed largely of community-based physicians is the
assumption that their characterization of clinical events
reflects diagnostic standards of the medical community,
and, as such, meets study criteria. However, with its large
number of endpoints, resources available to ALLHAT pre-
cluded more than modest confirmatory event documenta-
tion. Resources were allocated for additional
documentation for quality control validation only for a
sample of the primary endpoint (MIs and fatal CHD) and
for strokes. While all reported events are reviewed at the
CTC, the sometimes incomplete supporting details in
documentation may not allow for validation of all events
according to ALLHAT criteria. Some discharge summaries
and death certificates may lack sufficient descriptive infor-
mation needed to confirm the clinical diagnoses. Clinic
staff are unable to provide corroborating documentation
for 2% of ALLHAT event reports.
Efforts to authenticate the HF events in the doxazosin and
chlorthalidone treatment groups represented a desirable
step in the examination of the increased rate of HR in the
doxazosin group. All methods employed provided con-
firmatory evidence that both the HF diagnosis and the dif-
ference in HF rates noted between the doxazosin and
Figure 1
Kaplan-Meier estimates for cumulative mortality for hospitalized heart failure cases in the chlorthalidone and doxazosin groups
(RR 0.96, 95% CI, 0.67–1.38; P = 0.84)
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chlorthalidone groups were valid. Results of this explora-
tory investigation support the event ascertainment meth-
ods developed for ALLHAT, specifically for HF events. This
validation exercise further illustrates the ability of large,
simple trials to answer important public health questions
requiring large sample sizes and to grapple with unexpect-
ed results in a responsible and meaningful manner.
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Additional Information
1) New York Heart Classification functional class III: "Pa-
tients with cardiac disease resulting in marked limitation
of physical activity. They are comfortable at rest. Less than
ordinary physical activity causes fatigue, palpitation, dys-
pnea, or anginal pain." 1994 Revisions to Classification of
Functional Capacity and Objective Assessment of Patients
with Diseases of the Heart: AHA Medical/Scientific State-
ment.
2) The ALLHAT Manual of Operations provides for pre-
scription of open-label medicines of the same class as the
blinded medications, when a compelling indication ex-
ists, such that the total dose of the added open-label drug
should not exceed 1/2 of the maximum dose as recom-
mended in the Sixth Report of the Joint National Com-
mittee on Detection, Evaluation and Treatment of High
Blood Pressure (JNC VI). If a compelling reason requires a
higher dose, it is permitted.
3) The ALLHAT follow-up form allows for reporting of
open-label ACE-inhibitors and diuretics; among beta-
blockers, only atenolol is reported. The use of other beta-
blockers cannot be ascertained from the data.
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